Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AppliGel-G for Infected Diabetic Foot Ulcers
NCT02036528Phase 2Terminated
- Sponsor
- Royer Biomedical
- Start
- Jan 2014
- Primary completion
- Dec 2014
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AppliGel-G in diabetic foot ulcer (DFU) (2 arms), sponsored by Royer Biomedical. Primary endpoint: Complete wound clearing of infection at 28 days. Started Jan 2014; status: terminated.
02
Drugs
AppliGel-G
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02036528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036528.